Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)
- 6 February 2017
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 72 (5) , 1386-1395
Abstract
Objectives: To evaluate the in vitro activity of ceftolozane/tazobactam and comparators tested against European isolates of Enterobacteriaceae and Pseudomonas aeruginosa from hospitalized patients with urinary tract infection or intraabdominal infections. Methods: A total of 6553 Gram-negative organisms (603 P. aeruginosa and 5950 Enterobacteriaceae) were consecutively collected from 41 hospitals located in 17 European countries plus Israel and Turkey. The organisms were tested for susceptibility by broth microdilution methods and the results interpreted according to EUCAST and CLSI breakpoint criteria. Results: Ceftolozane/tazobactam [MIC50/90 0.25/1 mg/L; 93.5%/91.3% susceptible (S) (CLSI/EUCAST criteria)] and meropenem [MIC50/90 ≤0.06/≤0.06 mg/L; 98.1%/98.3% S (CLSI/EUCAST)] were the most active compounds tested against Enterobacteriaceae. Among the Enterobacteriaceae isolates, 1.9% were carbapenem resistant (CRE), 15.2% exhibited an ESBL non-CRE phenotype, 14.6% were MDR, 2.2% were XDR and 32/>32 mg/L; 3.6% S) or PDR (MIC50 >32 mg/L; 0.0% S) phenotype. Ceftolozane/tazobactam was the most potent (MIC50/90 0.5/4 mg/L) β-lactam agent tested against P. aeruginosa isolates, inhibiting 91.7% at an MIC of ≤4 mg/L. P. aeruginosa exhibited high rates of resistance to cefepime (20.6%), ceftazidime (23.1%), meropenem (9.0%) and piperacillin/tazobactam (26.9%) (EUCAST criteria). Among these four P. aeruginosa resistant phenotypes, 61.3%–70.4% were susceptible to ceftolozane/tazobactam. Conclusions: Ceftolozane/tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than currently available cephalosporins and piperacillin/tazobactam when tested against Enterobacteriaceae.Keywords
This publication has 22 references indexed in Scilit:
- Prevalence of Antimicrobial Use in US Acute Care Hospitals, May-September 2011JAMA, 2014
- Multistate Point-Prevalence Survey of Health Care–Associated InfectionsNew England Journal of Medicine, 2014
- The emergence of pan-resistant Gram-negative pathogens merits a rapid global political responseJournal of Antimicrobial Chemotherapy, 2011
- Appraising Contemporary Strategies to Combat Multidrug Resistant Gram-Negative Bacterial Infections–Proceedings and Data From the Gram-Negative Resistance SummitClinical Infectious Diseases, 2011
- How Can We Stem the Rising Tide of Multidrug-Resistant Gram-Negative Bacilli?Infection Control & Hospital Epidemiology, 2010
- Antibiotic Usage and ResistanceJAMA, 2009
- International Study of the Prevalence and Outcomes of Infection in Intensive Care UnitsJAMA, 2009
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance StudyClinical Infectious Diseases, 2004
- Nosocomial Candidiasis: Emerging Species, Reservoirs, and Modes of TransmissionClinical Infectious Diseases, 1996